Start Free Trial
Pricing
Log In
Log In
Upgrade browser for full Crunchbase experience. You're accessing Crunchbase in a browser that is no longer supported.
Learn More
Checkmab Logo
Checkmab CB Rank
741944
Heat Score
47
Checkmab aims to develop monoclonal antibodies against Treg cells in diseased tissues as immunotherapies against autoimmune diseases.
Founded
obfuscation
Private Milan, Lombardia, Italy1-10 www.checkmab.eu/
Biotechnology
Life Science
Product Research
Overview

Checkmab
Heat Score
47

Growth Score
pts
in past quarter
Heat Score 47
-9 pts
in past quarter

Company Performance Metrics

Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Learn More >
Recent Events
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience

About Checkmab

CB Rank
741944
Checkmab aims to develop monoclonal antibodies against Treg cells in diseased tissues as immunotherapies against autoimmune diseases.
Founded
obfuscation
Private Milan, Lombardia, Italy1-10 www.checkmab.eu/
Biotechnology
Life Science
Product Research

Details

Legal Name Checkmab Srl
Operating Status Active
Company Type For Profit
Phone Number +39-020-066-0220
Contact Email segreteria@checkmab.eu
Predictions & Insights

Growth Prediction

See this Growth Prediction

Products & Services

Therapeutic Monoclonal Antibodies Targeting Tumor-Infiltrating Regulatory T Cells (Tregs)
Monoclonal antibodies designed to selectively inhibit or deplete regulatory T cells infiltrating tumors to enable anti-tumor immune responses.

Research & Development

Checkmab is

obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
...

Unlock More with Crunchbase Pro
  • Full access to financial & funding data on unlimited profiles
  • Export up to 2k results/month for analysis
  • Track market signals on competitors, products, and R&D
  • Preview private company insights and predictions
Financials
Market Intelligence
People
View Profiles & Contacts
Headcount 1-10 Board Members and Advisors 1 Contacts 2

Board Members and Advisors

News

News and Press

News•Jun 12, 2023
obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated obfuscated
Access a complete feed of recent news and press, from product launches to leadership changes.
Technology
View Tech Report

Monthly Web Visits

357
257%
 in past month

IT Spend

$220.3KThis year, Checkmab is projected to spend $220.3K on IT, according to Aberdeen.

Active Website Tech Count

31Checkmab is actively using 31 technologies for its website, according to BuiltWith. These include SPF, Google Font API, and  SSL by Default.

Total IP

3The intellectual property of Checkmab includes 3 registered patents primarily in the 'Organic Chemistry' category, according to IPqwery.
Sub-Organizations
Frequently Asked Questions

Where is Checkmab's headquarters? Checkmab is located in Milan, Lombardia, Italy.Who are Checkmab's competitors? Alternatives and possible competitors to Checkmab may include Kyverna Therapeutics, Zag Bio, and  Quell Therapeutics.
Who We Are
What We Do
Helpful Links
AI Content may contain mistakes and is not legal, financial or investment advice. Learn more.
Terms of Service | Privacy Policy | Sitemap | © 2026 Crunchbase Inc. All Rights Reserved.
(bd7a319 1)
|